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Objectives The goal of this study was to compare the prognostic efficacy of the 6-min walk (6MW) and cardiopulmonary
exercise (CPX) tests in stable outpatients with chronic heart failure (HF).
Background CPX and 6MW tests are commonly applied as prognostic gauges for systolic HF patients, but few direct compari-
sons have been conducted.
Methods Stable New York Heart Association (NYHA) functional class II and III systolic HF patients (ejection fraction
35%) from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial
were studied. 6MW distance (6MWD) and CPX indices (peak oxygen consumption [VO2] and ventilatory equiva-
lents for exhaled carbon dioxide [VE/VCO2] slope) were compared as predictors of all-cause mortality/hospital-
ization and all-cause mortality over 2.5 years of mean follow-up.
Results A total of 2,054 HF-ACTION participants underwent both CPX and 6MW tests at baseline (median age 59 years; 71%
male; 64% NYHA functional class II and 36% NYHA functional class III/IV). In unadjusted models and in models that
included key clinical and demographic covariates, C-indices of 6MWD were 0.58 and 0.65 (unadjusted) and 0.62 and
0.72 (adjusted) in predicting all-cause mortality/hospitalization and all-cause mortality, respectively. C-indices for
peak VO2 were 0.61 and 0.68 (unadjusted) and 0.63 and 0.73 (adjusted). C-indices for VE/VCO2 slope were 0.56 and
0.65 (unadjusted) and 0.61 and 0.71 (adjusted); combining peak VO2 and VE/VCO2 slope did not improve the
C-indices. Overlapping 95% confidence intervals and modest integrated discrimination improvement values confirmed
similar prognostic discrimination by 6MWD and CPX indices within adjusted models.
Conclusions In systolic HF outpatients, 6MWD and CPX indices demonstrated similar utility as univariate predictors for all-
cause hospitalization/mortality and all-cause mortality. However, 6MWD or CPX indices added only modest prog-
nostic discrimination to models that included important demographic and clinical covariates. (J Am Coll
Cardiol 2012;60:2653–61) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1010Cardiopulmonary exercise (CPX) testing is generally re-
garded as the gold standard of aerobic assessment (1) with
the capacity to reliably discriminate differences along the
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accepted August 7, 2012.continuum of low to high exercise performance. This CPX
attribute has been incorporated into well-established appli-
cations to track performance (e.g., in relation to training or
therapy) and as means to distinguish mechanisms underly-
ing dyspnea and/or exercise limitations. CPX is also rou-
tinely applied as a prognostic tool. Peak oxygen uptake
(VO2) and the ventilatory equivalents for carbon dioxide
See page 2662
(VE/VCO2) slope are 2 CPX indices that have been
extensively validated as function-based prognostic assess-
ments (1–5), both independently and in combination (2,3).
The distance walked over 6 min is an alternative measure
of function that has also been applied as the basis of
function-based prognostic assessments (6,7). Compared
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HF Prognosis: 6-Min Walk Versus CPX Testing December 25, 2012:2653–61with the nontrivial costs and
logistical challenges of CPX testing,
a 6-minute walk (6MW) test is
significantly less expensive and
more convenient. Proponents of
the 6MW 4 test also emphasize
its distinctive value as a measure
of routine activity that may be
more clinically relevant than a
bicycle- or treadmill-based (7–9)
maximal functional evaluation.
We compared the prognostic
utility of 6MW and CPX testing
using baseline data from the HF-
ACTION (Heart Failure: A
Controlled Trial Investigating
Outcomes of Exercise Training)
trial (10), a randomized con-
trolled trial of an exercise train-
ing intervention for patients with
systolic heart failure (HF). The
HF-ACTION protocol entailed
6MW and CPX testing on the
same day as part of the baseline assessment.
We hypothesized that CPX indices would more accu-
rately discriminate all-cause hospitalization and mortality as
well as all-cause mortality over the trial’s 2.5-year mean
follow-up based on the assumption that gas exchange
assessment is more informative than simple distance walked.
We also expected that using CPX indices in combination
would add to CPX prognostic discrimination.
Methods
Details of the HF-ACTION protocol have been published
elsewhere (10). The study enrolled ambulatory systolic HF
patients identified by using clinical and echocardiographic
criteria (left ventricular ejection fraction [LVEF] 35%),
who were randomized to treatment with an aerobic exercise
training arm with usual care versus usual care alone. 6MW
and CPX were completed before randomization. Exercise
training entailed 36 supervised outpatient sessions plus
home training that was initially combined with the super-
vised sessions but which then continued independently for
the duration of follow-up. The ultimate goal was home
training, 5 days a week, using a treadmill or stationary cycle.
Patients were followed up over the course of the trial for
hospitalizations and mortality. The clinical endpoint com-
mittee that monitored these assessments remained blinded
to the patients’ assignments.
6MW tests were conducted in a standardized format,
with explicit instructions provided in the HF-ACTION
manual of operations, modeled after prior studies (11–13).
Each of the 82 HF-ACTION sites was instructed to
Abbreviations
and Acronyms
6MW  6-minute walk
6MWD  6-minute walk
distance
BMI  body mass index
CI  confidence interval
CPX  cardiopulmonary
exercise
ECG  electrocardiogram
HF  heart failure
HR  hazard ratio
IDI  integrated
discrimination improvement
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Association
VE/VCO2  ventilatory
equivalents for exhaled
carbon dioxide
VO2  oxygen consumptionmeasure a 20- to 25-m indoor course and to position a chair dat either end, providing subjects a place to rest if necessary.
L-shaped hallways were prohibited.
Consistent 6MW test methods were specified in the HF-
ACTION manual of operations, including standardized
phrasing (e.g., “cover as much ground as possible. . . keep
going. . . don’t worry if you have to sit down or stop to rest. . .”)
and consistent timing of encouragement (1-min intervals).
The HF-ACTION protocol was similarly uniform and
rigorous with regard to CPX methods. Symptom-limited
exercise testing was completed by using commercially avail-
able metabolic carts and motor-driven treadmills, employ-
ing a modified Naughton protocol (14). The respiratory
exchange ratio was used to gauge exercise effort; a ratio1.1
was targeted as a high effort standard (1).
Peak VO2 was determined in the CPX Core Laboratory
as the highest VO2 normalized to body mass (VO2, ml/kg/
in) for a given 15- or 20-s interval within the last 90 s of
xercise or the first 30 s of recovery, whichever was higher.
ean VE/VCO2 slope was calculated based on VE/VCO2
slope data across the entire duration of exercise using the
15- or 20-s averaged data for VCO2 (l/min) and VE
l/min); this method has previously been demonstrated to
aximize VE/VCO2 prognostic potential (15,16).
Statistical analysis. Statistical analyses were performed by
the Data Coordinating Center (Duke Clinical Research
Institute, Durham, North Carolina) by using SAS version
9.2 (SAS Institute Inc., Cary, North Carolina). The rela-
tionship of 6MW distance (6MWD) to baseline patient
characteristics was summarized by using medians with
interquartile range of 6MWD across categories of various
baseline attributes. Pearson correlation coefficients between
baseline characteristics and 6MWD were also calculated for
continuous variables.
Unadjusted Pearson correlation coefficients and adjusted
partial correlation coefficients were used to assess the associa-
tion between 6MWD and CPX parameters (peak VO2 and
E/VCO2 slope). The same set of covariates was used for both
eak VO2 and VE/VCO2 to adjust the correlations of the
iven CPX variable with 6MWD. Covariates used for adjust-
ent comprised all identified predictors from previously de-
eloped multivariable linear models of each exercise measure-
ent (6MWD and CPX measures) that were objectively
elected by using backward elimination methods (17).
As a measure of the degree to which a model accurately
iscriminates events from nonevents, C-index estimates
ith associated 95% confidence intervals (CIs) from unad-
usted and adjusted Cox proportional hazards models were
sed to compare the individual roles of 6MWD and CPX
easures (peak VO2 and VE/VCO2 slope) with respect to
he primary endpoint of all-cause hospitalization or mortal-
ty and the secondary endpoint of all-cause mortality. Peak
O2 and VE/VCO2 slope were assessed independently and
n combination within each prognostic model.
The 95% CI for the C-index in the various models served
s a surrogate for hypothesis tests to compare model
iscrimination. As a general rule, if 2 models of the same
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December 25, 2012:2653–61 HF Prognosis: 6-Min Walk Versus CPX Testingendpoint produce 95% CIs for the C-index that shared no
common values, they were regarded as significantly different
in terms of discrimination, whereas C-indices with widely
overlapping CIs were interpreted as lacking significant
differences between the 2 models.
6MWD and CPX indices were assessed within unad-
justed models (i.e., 6MWD and CPX indices as univariate
predictors) as well as in models adjusted for demographic
and clinical covariates. Baseline covariates used for the
adjustment were based on Cox proportional hazards models
that were previously developed for these endpoints. They
were selected using a stepwise method based on a bootstrap-
backward selection process (17). Relative risks associated
with normalized 6MWD and CPX measures were ex-
pressed as hazard ratios (HRs) with 95% CI.
To ensure comparability while optimizing sample size,
Cox models were applied to complete case data for patients
who had nonmissing values for 6MWD, peak VO2, and
E/VCO2 slope. All parameters were converted to standard
ormal z-scores before their inclusion in the Cox models,
nd the model assumption of linearity was assessed with
espect to each standardized measure. Examination of cubic
plines revealed that the relationship of 6MWD to the
ortality/hospitalization endpoint was constant beyond 1
D from the mean value; for this reason, the 6MWD
elationship was truncated, and the HR for values of
MWD 1 SD beyond the mean was set to 1 (i.e., no
dditional relationship of the measure with death/
ospitalization beyond that point).
The integrated discrimination improvement (IDI) statis-
ic was calculated to assess the relative impact of introducing
ach exercise measure to the models adjusted for demo-
raphic and clinical variables (18). The IDI examines
odels in terms of degree of discrimination, as measured by
he separation between mean predicted probabilities among
atients with and without endpoints in each model. Con-
inuous variables are expressed as median (25th and 75th
ercentiles) and discrete variables as percentages. For all
nalyses, a 2-tailed p value 0.05 was required to reject the
ull hypothesis.
Baseline CharacteristicsTable 1 Baseline Characteristics
Parameter n Median IQR: 25th, 75th
Age (yrs) 2,054 59 51, 68
BMI (kg/m2) 2,049 30.1 26.3, 35.4
Height (cm) 2,049 173 166, 180
6MWD (m) 2,054 372 300, 434
Peak VO2 (ml/kg/min) 2,030 14.6 11.7, 17.7
VE/VCO2 slope 2,030 32.4 28.1, 38.3
Sex (male/female) 1,459/595 71%/29% —
NYHA functional class
(class II/class III/IV)
1,317/737 64%/36% —
6MWD  6-min walk distance; BMI  body mass index; IQR  interquartile range; NYHA  NewL
York Heart Association; VO2 oxygen consumption; VE/VCO2 ventilatory equivalents for exhaled
arbon dioxide.esults
f the 2,331 patients enrolled in HF-ACTION, 211
ubjects underwent CPX testing on cycle ergometers and
ere excluded from the analysis. In 20 other subjects,
ecause it was unclear whether a cycle or treadmill had been
sed during the CPX test, they also were excluded. Of the
,100 patients who remained, 2,054 had both 6MW and
PX test data. These 2,054 patients (88% of the original
F-ACTION population) represent the cohort for this
nalysis. Within this group, 2,030 patients had both
MWD and peak VO2 measurements, and 2,013 had
MWD, peak VO2, and VE/VCO2 slope measurements.
Table 1 shows the distribution of baseline patient char-
acteristics in the study population, generally indicative of a
middle-aged cohort with mild to moderate functional im-
pairment. Figure 1 illustrates the distribution of 6MWD
ata, highlighting the wide range of walking capacities and
early symmetric distribution of 6MWD in the HF-
CTION study population.
Table 2 shows the distribution of 6MWD values accord-
ng to various key clinical characteristics, with Pearson
orrelation coefficients for continuous attributes. Older age
r  –0.23) and higher body mass index (BMI) (r  –0.13)
orrelated with shorter 6MWD among the continuous
ariables. Sex, race, New York Heart Association (NYHA)
unctional class, and other categorical variables also demon-
trated significant relationships with 6MWD.
Table 3 shows unadjusted and adjusted correlations
etween 6MWD and CPX parameters. Significant covari-
tes used in the adjusted model were height, weight,
umber of hospitalizations during the 6 months before
aseline, geographic region, NYHA functional class (II vs.
II/IV), age, race, peripheral vascular disease, electrocardio-
ram (ECG) ventricular conduction abnormality, BMI, sex,
Figure 1 Distribution of 6MWD in
the HF-ACTION Study Population
Six-minute walk distance (6MWD) varied widely among participants of the
HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exer-
cise Training) trial, which afforded an excellent opportunity to assess its
prognostic efficacy.VEF, and diabetes mellitus. Although 6MWD correlated
c left bu
R
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HF Prognosis: 6-Min Walk Versus CPX Testing December 25, 2012:2653–61significantly with both peak VO2 and VE/VCO2 slope,
with or without adjustment for covariates, correlations were
slightly stronger with peak VO2 in each case. After adjust-
ing for covariates, correlations of both CPX indices with
6MWD were substantially weaker, indicating the degree to
which covariates may have accounted for the unadjusted
correlations.
The respective contributions of 6MWD, peak VO2, and
VE/VCO2 slope to unadjusted and adjusted models of
Distribution of 6MWD According to Baseline CharacteristicsTable 2 Distribution of 6MWD According to Baseline Characte
Variables Category
Age 40 yrs
40–59
60–69
70 yrs
BMI 27.6
27.6–33.1
33.1
LVEF 21.5
21.5–28.2
28.2
Carvedilol equivalents (mg/day) Low dose (30)
High dose (30)
BDI II 6
6–11
12
Sex Male
Female
Race White
Black
Other
Country United States
Canada
NYHA functional class II
III
CCS angina class No angina
Class I
Class II–IV
HF etiology Ischemic
Nonischemic
Mitral regurgitation Low (none to moderate)
High (severe)
ECG vent cond before baseline CPX Normal
LBBB
RBBB
IVCD
Paced
Diabetes No
Yes
PAD No
Yes
COPD No
Yes
BDI  Beck Depression Index; CCS  Canadian Cardiovascular Society; COPD  chronic obstru
onduction abnormality; HF  heart failure; IVCD  intraventricular conduction delay; LBBB 
BBB  right bundle branch block; other abbreviations as in Table 1.all-cause hospitalization/mortality and mortality are shownin Tables 4 and 5, respectively. The HRs were closer to 1 for
the given exercise parameter in the adjusted model, com-
pared with the HR in the unadjusted model. However, the
C-index was higher in the adjusted model than the unad-
justed model; that is, with more variables in the adjusted
model, the overall discrimination improved.
Although chi-square tests confirm the significant associ-
ation of 6MWD, peak VO2, and VE/VCO2 slope with
both endpoints even after inclusion of common clinical and
s
n
6MWD Median
(IQR: 25th, 75th)
Pearson Correlation
(for Continuous Variables)
153 407 (346, 457) –0.23
933 385 (307, 450)
558 366 (305, 425)
410 332 (262, 391)
676 376 (307, 439) –0.13
677 383 (307, 442)
696 358 (290, 424)
676 363 (287, 427) 0.06
673 379 (304, 439)
695 373 (310, 434)
1,021 366 (296, 430) 0.04
1,015 375 (302, 439)
656 387 (322, 442) –0.12
729 373 (301, 439)
664 355 (274, 421)
1,459 380 (304, 441)
595 354 (290, 415)
1,216 384 (313, 445)
697 349 (280, 416)
111 385 (320, 439)
1,874 371 (300, 435)
180 375 (300, 424)
1,317 396 (335, 454)
737 319 (252, 386)
1,695 371 (300, 433)
186 387 (326, 449)
171 356 (282, 410)
1,043 366 (293, 429)
1,011 380 (307, 442)
1,667 376 (305, 440)
227 366 (274, 420)
868 378 (305, 442)
319 385 (315, 449)
76 366 (305, 427)
273 366 (296, 420)
469 356 (287, 420)
1,384 384 (314, 442)
670 348 (274, 411)
1920 374 (304, 436)
124 321 (238, 404)
1,819 376 (305, 428)
218 327 (262, 405)
ng disease; CPX  cardiopulmonary exercise; ECG vent cond  electrocardiogram ventricular
ndle branch block; LVEF  left ventricular ejection fraction; PAD  peripheral arterial disease;ristic
ctive lulaboratory covariates, the small IDI estimates associated
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December 25, 2012:2653–61 HF Prognosis: 6-Min Walk Versus CPX Testingwith inclusion of these exercise test variables in adjusted
models suggest that they contribute only a modest degree of
added discrimination. The addition of peak VO2 to the
adjusted model of the primary endpoint (all-cause hospital-
ization/mortality) produced the highest IDI (0.04), with
6MWD producing an IDI of 0.02 in that model. The IDI
was 0.01 for the addition of each of these 3 measures to
the adjusted model of mortality. The widely overlapping
95% CIs for the C-index estimates of models containing
each of the 3 exercise measures, as well as similar IDI values
in the adjusted models, suggest that 6MWD and CPX
measures do not differ significantly from each another in
their prognostic discrimination of these endpoints.
Table 6 displays the C-indices pertaining to normalized
6MWD and CPX measures in models of all-cause hospi-
talization/mortality and all-cause mortality, respectively. In
an unadjusted model of all-cause hospitalization/mortality,
the C-index (0.58) associated with 6MWD (truncated at 1
SD above the mean as described earlier) was numerically
lower than the C-index of peak VO2 (0.61) and greater than
the C-index associated with VE/VCO2 (0.56). The
6MWD and CPX measures were also assessed relative to an
adjusted model with the covariates: sex, region (United
States/non–United States), mitral regurgitation, ECG ven-
tricular conduction abnormality, blood urea nitrogen,
LVEF, beta-blocker dose, and the Kansas City Cardiomy-
opathy Questionnaire, a 23 item disease-specific health
status measure for heart failure patients. Without peak VO2,
VE/VCO2, or 6MWD, the model predicted all-cause
hospitalization/mortality, with a C-index of 0.60. Adding
6MWD to the model increased the C-index to 0.62.
Correlations of 6MWD to CPX IndicesTable 3 Correlations of 6MWD to CPX Indic
Parameter n
Unadjuste
Adjus
Peak VO2 (ml/kg/min) 2,030 Unadju
1,920 Adjust
VE/VCO2 slope 2,014 Unadju
1,905 Adjust
*Adjusted correlations are the partial correlations from models includ
Abbreviations as in Tables 1 and 2.
Prognostic Utility of 6MWD Versus CPX Indices in Predicting All-CaTable 4 Prognostic Utility of 6MWD Versus CPX Indices in Pre
Model Parameter Chi-Square Statistic
Unadjusted univariate predictors 6MWD‡ (Z 1) 99
Peak VO2 158
VE/VCO2 slope 85
Adjusted§ 6MWD‡ (Z 1) 48
Peak VO2 80
VE/VCO2 slope 19
*Hazard ratio based on z-score. †Integrated discrimination improvement (IDI) model includes 2,01
t 1 SD in the model of hospitalization/mortality because of its lack of relationship with this endpo
o 1. Other truncated covariates are carvedilol equivalent dose: truncated above 50 mg/day; BMI:
odel adjusted for sex, region (United States vs. non–United States), mitral regurgitation, ECG
uestionnaire symptom stability score. All-cause mortality model adjusted for sex, BMI, loop diuretic dos
Other abbreviations as in Tables 1 and 2.Adding peak VO2 (instead of 6MWD) increased the
C-index to 0.63. Adding VE/VCO2 slope (instead of
6MWD or peak VO2) increased the C-index to 0.61. When
eak VO2 and VE/VCO2 slope were used in combination
within the model, C-index increased to 0.63, no better than
the same model minus VE/VCO2 slope. Combining
6MWD and peak VO2 within the model increased the
-index to 0.64. However, when all 3 functional indices
6MWD, peak VO2, and VE/VCO2 slope) were used in the
model together, the C-index remained at 0.64. Notably,
when peak VO2 and VE/VCO2 slope were entered into the
odel together, peak VO2 had a larger influence on
rognosis (p 0.001) whereas the impact of the VE/VCO2
slope was nonsignificant (p  0.57).
Table 6 also displays the C-indices relating 6MWD and
CPX measures to all-cause mortality. In unadjusted models,
the C-index associated with peak VO2 (0.68) was slightly
igher than the C-index associated with 6MWD (0.65).
owever, C-indices of 6MWD and VE/VCO2 slope (0.65)
were equivalent. In a model for all-cause mortality with the
covariates sex, BMI, loop diuretic dose, Canadian angina
class, ECG ventricular conduction abnormalities, LVEF,
and serum creatinine, the C-index was 0.69. Adding
6MWD, peak VO2, and VE/VCO2 slope individually to
the model increased the C-indices to 0.72, 0.73, and 0.71,
respectively. Combining the functional indices modestly
increased prognostic discrimination; the C-index increased
to 0.74 with any combination of the functional indices
(C-index  0.74 in relation to 6MWD and peak VO2 or to
eak VO2 and VE/VCO2 slope or to 6MWD, peak VO2,
nd VE/VCO2 slope).
sus
Correlation With 6MWD p Value
0.54 0.0001
0.33 0.0001
–0.26 0.0001
–0.17 0.0001
ariates in the final adjusted model of 6MW or any CPX parameter.
Hospitalization/Mortalityg All-Cause Hospitalization/Mortality
alue
Hazard Ratio*
(95% Confidence Interval)
C-Index
(95% Confidence Interval) IDI†
001 0.75 (0.70–0.79) 0.58 (0.57–0.60)
001 0.69 (0.65–0.73) 0.61 (0.59–0.62)
001 1.27 (1.21–1.33) 0.56 (0.55–0.58)
001 0.78 (0.73–0.84) 0.62 (0.60–0.64) 0.019
001 0.72 (0.67–0.77) 0.63 (0.61–0.65) 0.043
001 1.15 (1.08–1.22) 0.61 (0.59–0.62) 0.009
nts with nonmissing values for 6MW, peak VO2, and VE/VCO2. ‡6MWD (normalized) is truncated
ond that point. Truncation in this case implies that the hazard ratio for values of 6MWD 1 is set
ted above 25 kg/m2; creatinine: truncated above 2.3 mg/dl. §All-cause hospitalization/mortality
cond, blood urea nitrogen, LVEF, carvedilol equivalent dose, and Kansas City Cardiomyopathyes
d Ver
ted*
sted R
ed R*
sted R
ed R*usedictin
p V
0.0
0.0
0.0
0.0
0.0
0.0
3 patie
int bey
trunca
vente, angina class, ECG vent cond, LVEF, and creatinine.
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HF Prognosis: 6-Min Walk Versus CPX Testing December 25, 2012:2653–61Discussion
In this secondary analysis from HF-ACTION, we found
that a 6MW test provides useful prognostic information for
both the composite outcome of all-cause hospitalization/
mortality as well as the outcome of all-cause mortality in
NYHA functional class II and III HF outpatients receiving
state-of-the-art therapy for systolic HF. In both unadjusted
and adjusted models, the prognostic information provided
by 6MWD, as estimated by using the C-index, was similar
to that for peak VO2 and VE/VCO2 slope attained by using
PX testing even when peak VO2 and VE/VCO2 slope
ere assessed in combination. Although the C-statistic to
redict all-cause hospitalization/mortality and all-cause
ortality for CPX testing was numerically larger than that
or 6MWD, the difference was too small to be clinically
eaningful. Individually, 6MWD and peak VO2 provided
imilar levels of discrimination as univariate predictors; unad-
usted models of either exercise parameter predicting hospital-
zation/mortality or all-cause mortality had discrimination that
pproached that of models with known clinical and demo-
raphic covariates without exercise parameters. However, there
as little augmentation in discrimination resulting from the
ddition of either exercise measure to the adjusted models.
Prognostic Utility of 6MWD Versus CPX Indices in Predicting All-CaTable 5 Prognostic Utility of 6MWD Versus CPX Indices in Pre
Model Parameter Chi-Square Statistic
Unadjusted univariate predictors 6MWD 94
Peak VO2 123
VE/VCO2 slope 130
Adjusted† 6MWD 55
Peak VO2 77
VE/VCO2 slope 45
*Hazard ratio based on z-score. †All-cause hospitalization/mortality model adjusted for sex, regio
arvedilol equivalent dose, and Kansas City Cardiomyopathy Questionnaire symptom stability scor
nd creatinine.
Other abbreviations as in Tables 1 and 2.
C-Index of 6MWD Versus CPX Indices in Unadjusted and AdjustedAll-Cause Hospitalization/Mortality and All-Cause MortalityTable 6 C-Index of 6MWD Versus CPX In ic s in Unadjusted aAll-Cause Hospitalization/Mortality and All-Cause Mort
Variable
All-Caus
Unadjuste
Model without 6MWD, peak VO2, or VE/VCO2 slope NA
Model with 6MWD* 0.58
Model with peak VO2 0.61
Model with VE/VCO2 slope 0.56
Model with peak VO2 and VE/VCO2 slope 0.61
Model with peak VO2 and 6MWD* 0.61
Model with peak VO2 and VE/VCO2 slope and 6MWD* 0.61
Model p
mitral r
BUN, LV
KCCQ s
Unadjustedmodel contains only the stated exercise variable(s). Adjustedmodel includes the given e
of hospitalization/mortality because of its lack of relationship with this endpoint beyond that point
covariates are carvedilol equivalent dose: truncated above 50 mg/day; BMI: truncated above 25 kg/m ;
BUN  blood urea nitrogen; KCCQ  Kansas City Cardiomyopathy Questionnaire; NA  not applicableTable 7 lists many of the landmark studies (2,19–27) that
alidated the 6MW test as a prognostic measure for systolic
F patients and those which compared it with CPX testing.
hese and related studies (28–31) were small; enrolled
atients with different etiologies and severities of HF; and
sed variable protocols to administer the tests. Heterogene-
ty of results is thus not surprising (31).
Compared with previous studies, HF-ACTION stands
ut for its larger study population, comprehensive assess-
ents, and emphasis on contemporary evidence–based
herapy. Our data are noteworthy in showing efficacy of
MWD as a continuous prognostic marker among a large
F population with a wide range of performance capacities,
early all of whom were receiving beta-blockers, angiotensin-
onverting enzyme inhibitors, or angiotensin receptor block-
rs. Whereas prior literature demonstrated greatest 6MWD
rognostic discrimination for patients with very low perfor-
ance, in the current study, 6MWD was predictive across a
ide spectrum of performance capacities and essentially
atched the efficacy of CPX testing as a prognostic tool
cross the full range of patients.
A notable attribute of the HF-ACTION protocol was
hat it provided explicit instructions on how to implement
Mortalityg All-Cause Mortality
alue
Hazard Ratio*
(95% Confidence Interval)
C-Index
(95% Confidence Interval) IDI
001 0.61 (0.55–0.67) 0.65 (0.62–0.68)
001 0.48 (0.42–0.55) 0.68 (0.65–0.71)
001 1.58 (1.46–1.71) 0.65 (0.61–0.68)
001 0.65 (0.57–0.73) 0.72 (0.69–0.75) 0.005
001 0.51 (0.44–0.59) 0.73 (0.71–0.76) 0.010
001 1.37 (1.25–1.51) 0.71 (0.68–0.74) 0.004
ed States vs. non–United States), mitral regurgitation, ECG vent cond, blood urea nitrogen, LVEF,
use mortality model adjusted for sex, BMI, loop diuretic dose, angina class, ECG vent cond, LVEF,
ls ofjusted Models of
pitalization/Mortality All-Cause Mortality
Adjusted Unadjusted Adjusted
0.60 NA 0.69
0.62 0.65 0.72
0.63 0.68 0.73
0.61 0.65 0.71
0.63 0.70 0.74
0.64 0.69 0.74
0.64 0.71 0.74
ters are sex, region,
ation, ECG vent cond,
vedilol equivalent dose,
stability score
Model parameters are sex, BMI, loop
diuretic dose, angina class, ECG
conduct abnl, LVEF, Cr
variable(s) plus themodel covariates listed. *6MWD (normalized) is truncated at 1 SD in themodel
ation in this case implies that the hazard ratio for values of 6MWD 1 is set to 1. Other truncatedusedictin
p V
0.0
0.0
0.0
0.0
0.0
0.0
n (Unit
e. All-caModend Ad
ality
e Hos
d
arame
egurgit
EF, car
ymptom
xercise
. Trunc
2 and creatinine (Cr): truncated above 2.3 mg/dl.
; region  United States versus non–United States; other abbreviations as in Tables 1 and 2.
an
c
t
p
V
m
a
h
m
(
f
r
c
S
c
p
2659JACC Vol. 60, No. 25, 2012 Forman et al.
December 25, 2012:2653–61 HF Prognosis: 6-Min Walk Versus CPX Testingthe 6MW test. Although proponents of the 6MW test often
emphasize the ease and convenience of its application, incon-
sistencies in its administration may inadvertently diminish the
reliability of the results (32). In HF-ACTION, significant
efforts were undertaken to standardize optimal techniques for
both 6MW and CPX testing, thus providing a robust com-
parison between these 2 performance assessments.
Baseline 6MWD correlated more strongly with peak
VO2 than with VE/VCO2 slope, suggesting that 6MWD
nd peak VO2 share more physiological underpinnings (33).
Cardiac output, peripheral perfusion capacity, and skeletal
muscle health are integral to each of these performance
measures, and differ from the physiological determinants
underlying VE/VCO2 slope (e.g., ventilation-perfusion ab-
ormalities, chemoreceptor responses, intrinsic respiratory
6MW Test to Predict HF Outcomes and Studies Comparing 6MW aTable 7 6MW Test to Predict HF Outcomes and Studies Comp
Prior Study Study Population
6MW test as a prognostic marker
Bittner et al. (19) 833 patients
● LVEF 37 14%
● NYHA functional class 1.8
● 15% on beta-blockers
Bettencourt et al. (20) 139 patients
● LVEF 33.5 13.2%
● NYHA functional class 1.9;
● 25.2% on beta-blockers
Ingle et al. (21) 1,592 HF patients
● Mean LVEF 48%; range 35%–56%
● NYHA functional class I–IV (specific p
not clarified)
● 42.2% on beta-blockers
6MW test for prognostication
compared with CPX test
Cahalin et al. (22) 45 patients
● LVEF 20 6%
● NYHA functional class 3.3
● Beta-blocker unreported
Roul et al. (23) 121 patients
● LVEF 29 13
● NYHA functional class 2.4
● Beta-blocker unreported
Zugck et al. (24) 113 patients
● LVEF 19 7%
● NYHA functional class 2.2
● 17% using beta-blocker
Lucas et al. (25) 307 patients
● LVEF 23% average
● Patients under evaluation for transpl
Opasich et al. (26) 315 HF patients
● Mean LVEF 26 8%
● NYHA functional class 2.4
● Beta-blocker not reported
Guazzi et al. (2) 253 HF patients
● LVEF 36.3 11.4%
● NYHA functional class 2.2 0.78
● 58.5% on beta-blockers
Rostagno et al. (27) 214 patients
● LVEF 42%
● NYHA functional class 2.1
● 25% on beta-blockers
Abbreviations as in Tables 1 and 2.apacity, cardiopulmonary coupling) (3). Although we therefore expected that VE/VCO2 slope would add inde-
endent value to the prognostic model that included peak
O2, this was not the case. VE/VCO2 slope added only
inor prognostic enhancement.
The prognostic efficacy of 6MWD demonstrated in this
nalysis resonates with a multitude of recent literature
ighlighting the prognostic utility of other walking assess-
ents such as gait speed and the 400-m corridor walk
34,35). The physiological principles underlying these dif-
erent assessments of walking capacity seem similar, and
einforce the value of the 6MW test as a valid, sensitive, and
linically meaningful prognostic tool.
trengths and limitations. As the largest randomized
ontrolled trial of exercise training ever conducted in HF
atients, HF-ACTION provided an unparalleled opportunity
PX6MW and CPX
Results
300 m quartile: Significantly greater chance of death
(10.23% vs. 2.99%; p  0.01), hospitalization (40.91% vs.
19.90%; p  0.002), and HF hospitalization (22.16% vs.
1.99%; p  0.0001).
350 m independently predicted all-cause mortality
ions
6MWD independently predicted mortality among patients with
mild left ventricular systolic dysfunction
● 6MWD correlated with peak VO2 (r  0.64, p  0.001)
● 6MWD 300 m predicted a combined endpoint of death
and/or hospitalization for transplant (p  0.04)
● 6MWD correlated to peak VO2 for patients who walked
300 m (r  0.65)
● Events significantly higher in those who walked 300 m
● 6MWD correlated strongly with peak VO2 (r  0.68)
● 6MWD prognostic assessment similar to peak VO2
● Shorter 6MWD correlated to lower peak VO2
● Peak VO2 predicted survival, but 6MWD did not
● 6MWD is a univariate prognostic marker
● When entered into a model with NYHA and peak VO2,
prognostic value of 6MWD diminished
● 6MWD correlated with peak VO2 and VE/VCO2 slope but did
not predict mortality
● Survival significantly lower among those who walked 300 m
● Peak VO2 provided no prognostic valuend Caring
roport
anto compare the prognostic utility of 6MW and CPX testing in
v
c
c
a
t
d
t
f
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HF Prognosis: 6-Min Walk Versus CPX Testing December 25, 2012:2653–61this common clinical setting. Thus, the large sample size and
rigorous protocol for performing both tests in a contemporary
HF population receiving evidence-based drug and device
therapy represent major strengths of the current study.
Certain limitations should also be recognized. Because
HF-ACTION is an exercise training trial, the exercise
intervention may have affected the relationship between
functional assessments and outcomes. However, this treat-
ment effect has similar bearing on 6MW and CPX assess-
ments and does not confound the analysis.
Although CPX tests were repeated on approximately 400
HF-ACTION subjects to exclude familiarization (36),
similar assessments of possible familiarization effects were
never made in relation to 6MW tests in HF-ACTION.
Other studies have suggested this may have bearing on
6MWD assessments (37). Therefore, it cannot be assumed
that 6MWD assessments will consistently provide equiva-
lent prognostic discrimination when used for serial evalua-
tions. Nonetheless, the fact that the initial 6MWD assess-
ments yielded prognostic information similar to that of
CPX tests suggests that the predictive implications of
walking distance are robust.
Although HRs associated with standardized values of
6MWD and the CPX measures are provided in the tables,
comparisons of these ratios should be made with caution.
Given the fundamental differences in the nature of the
various exercise measures, the risk associated with 1 SD
difference in a given measure may not be directly compara-
ble to the risk associated with an equivalent difference in
another measure. The HF-ACTION protocol entailed
completing 6MW and CPX testing at the same baseline
visit, eliminating fluctuations in mood, health, or other
clinical dynamics that would have been more likely if tests
were performed on separate days. However, the protocol did
not randomize the order in which the 6MW and CPX tests
were conducted; because the 6MW test generally preceded
the CPX test, this may have biased the results.
Although our data indicate that 6MWD or CPX indices
peak VO2 and VE/VCO2 slope add only modest prognostic
alue to models that already include demographic and
linical covariates that could be gathered as part of a
omprehensive clinical assessment, both tests provide useful
ssessments of a patient’s aerobic capacity. In addition, CPX
esting may be more likely to detect exercise-related hemo-
ynamic instability, ischemia, arrhythmias, and symptoms
hat are clinically important (1) but that were outside the
ocus of this investigation.
Finally, in addition to peak VO2 and VE/VCO2 slope,
CPX provides the potential to assess several additional
indices that may increase prognostic information. Oscilla-
tory expiratory breathing, end-tidal partial pressure of car-
bon dioxide, VE/VO2 ratios, recovery gas exchange dynam-
ics, and heart rate and blood pressure responses are among
an extensive array of CPX assessments that can be used to
enhance prognostic assessment (1,2,38). Although this
study highlights the utility of 6MWD relative to the 2 mostcommonly reported indices of CPX testing, it does not
address the utility of a comprehensive CPX evaluation.
Conclusions
The 6MW test provided useful prognostic information for
all-cause hospitalization and mortality among stable NYHA
functional class II and III HF patients receiving state-of-
the-art therapy. Although CPX testing is often assumed to
provide superior function-based prognostic assessment in
HF patients, we demonstrated that 6MWD provided prog-
nostic value that was similar to peak VO2, VE/VCO2 slope,
and their combination in a relatively stable HF population.
These data suggest that a 6MW test may be substituted for
CPX testing as an inexpensive, practical clinical tool to help
gauge prognosis in the large and growing HF population.
Although 6MWD and peak VO2 both demonstrated utility
as univariate predictors in unadjusted prognostic models for
all-cause hospitalization/mortality and all-cause mortality,
both measures added only modest prognostic discrimination
to models that included important demographic and clinical
covariates.
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